Applied DNA Reports Third Quarter Fiscal 2025 Financial Results
Applied DNA Sciences (NASDAQ:APDN) reported its Q3 fiscal 2025 financial results, highlighting its transition to a pure-play provider of synthetic DNA and mRNA manufacturing solutions through its LineaRx subsidiary. The company reported revenues of $304,000, down from $473,000 in Q3 2024, with an operating loss of $3.7 million.
The company is commercializing three key technologies: 尝颈苍别补顿狈础鈩� (cell-free DNA production platform), 尝颈苍别补搁狈础笔鈩� (next-generation T7 RNA polymerase), and 尝颈苍别补滨痴罢鈩� (integrated system). Notable achievements include a $600,000+ follow-on order for LineaDNA and reduced monthly cash burn by 19% sequentially. The company ended the quarter with $4.7 million in cash.
Applied DNA Sciences (NASDAQ:APDN) ha comunicato i risultati del terzo trimestre fiscale 2025, confermando la sua trasformazione in un fornitore puro di DNA sintetico e soluzioni di produzione di mRNA tramite la controllata LineaRx. La societ脿 ha registrato ricavi per 304.000 dollari, in calo rispetto a 473.000 dollari nel Q3 2024, e un perdita operativa di 3,7 milioni di dollari.
Sta commercializzando tre tecnologie chiave: 尝颈苍别补顿狈础鈩� (piattaforma di produzione di DNA cell-free), 尝颈苍别补搁狈础笔鈩� (polimerasi T7 di nuova generazione) e 尝颈苍别补滨痴罢鈩� (sistema integrato). Tra i risultati rilevanti figurano un ordine di follow-on superiore a 600.000 dollari per LineaDNA e una riduzione del burn rate mensile del 19% su base sequenziale. La liquidit脿 a fine trimestre era di 4,7 milioni di dollari.
Applied DNA Sciences (NASDAQ:APDN) present贸 sus resultados del tercer trimestre fiscal de 2025, subrayando su transici贸n a proveedor puro de ADN sint茅tico y soluciones de fabricaci贸n de ARNm a trav茅s de su filial LineaRx. La compa帽铆a report贸 ingresos de 304.000 d贸lares, frente a 473.000 d贸lares en el Q3 de 2024, y una p茅rdida operativa de 3,7 millones de d贸lares.
Est谩 comercializando tres tecnolog铆as clave: 尝颈苍别补顿狈础鈩� (plataforma de producci贸n de ADN libre de c茅lulas), 尝颈苍别补搁狈础笔鈩� (polimerasa T7 de nueva generaci贸n) y 尝颈苍别补滨痴罢鈩� (sistema integrado). Logros notables incluyen un pedido de seguimiento superior a 600.000 d贸lares para LineaDNA y una reducci贸n del gasto mensual en efectivo del 19% secuencialmente. La compa帽铆a cerr贸 el trimestre con 4,7 millones de d贸lares en efectivo.
Applied DNA Sciences (NASDAQ:APDN)電� 2025 須岅硠鞐半弰 3攵勱赴 鞁れ爜鞚� 氚滍憸頃橂┌ 鞛愴殞靷� LineaRx毳� 韱淀暣 頃╈劚 DNA 氚� mRNA 鞝滌“ 靻旊（靺橃潣 靾滌垬 頂岆爤鞚挫柎搿� 鞝勴櫂 欷戩瀯鞚� 臧曥“頄堨姷雼堧嫟. 須岇偓電� 30毵�4觳� 雼煬鞚� 毵れ稖鞚� 氤搓碃頄堨溂氅�(2024雲� 3攵勱赴 47毵�3觳� 雼煬鞐愳劀 臧愳唽), 鞓侅梾靻愳嫟 370毵� 雼煬毳� 旮半頄堨姷雼堧嫟.
須岇偓電� 靹� 臧�歆� 頃奠嫭 旮办垹鞚� 靸侅毄頇旐晿瓿� 鞛堨姷雼堧嫟: 尝颈苍别补顿狈础鈩�(氍挫劯韽� DNA 靸濎偘 頂岆灚韽�), 尝颈苍别补搁狈础笔鈩�(彀劯雽� T7 RNA 欷戫暕須唽), 尝颈苍别补滨痴罢鈩�(韱淀暕 鞁滌姢韰�). 欤检殧 靹标臣搿滊姅 LineaDNA鞐� 雽�頃� 60毵� 雼煬 鞚挫儊 頉勳啀 欤茧瓿� 鞗旉皠 順勱笀 靻岇毳犾澊 鞝勲秳旮� 雽�牍� 19% 臧愳唽頃� 鞝愳澊 鞛堨姷雼堧嫟. 攵勱赴 毵� 順勱笀 鞛旍暋鞚� 470毵� 雼煬鞛呺媹雼�.
Applied DNA Sciences (NASDAQ:APDN) a publi茅 ses r茅sultats du troisi猫me trimestre fiscal 2025, mettant en avant sa transition vers un fournisseur pur de solutions de fabrication d'ADN synth茅tique et d'ARNm via sa filiale LineaRx. La soci茅t茅 a d茅clar茅 des revenus de 304 000 dollars, en baisse par rapport 脿 473 000 dollars au T3 2024, et une perte d'exploitation de 3,7 millions de dollars.
Elle commercialise trois technologies cl茅s : 尝颈苍别补顿狈础鈩� (plateforme de production d'ADN sans cellules), 尝颈苍别补搁狈础笔鈩� (polym茅rase T7 de nouvelle g茅n茅ration) et 尝颈苍别补滨痴罢鈩� (syst猫me int茅gr茅). Parmi les r茅alisations notables figurent une commande de suivi de plus de 600 000 dollars pour LineaDNA et une r茅duction du burn mensuel de 19 % en s茅quentiel. La soci茅t茅 cl么turait le trimestre avec 4,7 millions de dollars en liquidit茅s.
Applied DNA Sciences (NASDAQ:APDN) meldete die Finanzergebnisse f眉r das dritte Quartal des Gesch盲ftsjahres 2025 und betonte den Wandel zur reinen Anbieterin synthetischer DNA- und mRNA-Fertigungsl枚sungen 眉ber die Tochtergesellschaft LineaRx. Das Unternehmen erzielte Ums盲tze von 304.000 US-Dollar, nach 473.000 US-Dollar im Q3 2024, und verzeichnete einen operativen Verlust von 3,7 Millionen US-Dollar.
Kommerzialisierte Kerntechnologien sind 尝颈苍别补顿狈础鈩� (zellfreie DNA-Produktionsplattform), 尝颈苍别补搁狈础笔鈩� (Next鈥慓eneration T7-RNA鈥慞olymerase) und 尝颈苍别补滨痴罢鈩� (integriertes System). Zu den bemerkenswerten Erfolgen z盲hlen ein Follow鈥憃n鈥慉uftrag von 眉ber 600.000 US-Dollar f眉r LineaDNA und eine Reduzierung des monatlichen Cash鈥態urns um 19% gegen眉ber dem Vorquartal. Zum Quartalsende verf眉gte das Unternehmen 眉ber 4,7 Millionen US-Dollar in bar.
- Secured $600,000+ follow-on order for LineaDNA from global IVD manufacturer
- Monthly net cash burn reduced by 19% sequentially and 25% year-over-year
- Successfully expanded customer base with new U.S.-based mRNA contract development manufacturing organization
- Initiated ISO 13485 certification process for enhanced market opportunities
- Revenue declined to $304,000 from $473,000 in Q3 2024
- Operating loss increased to $3.7 million from $3.3 million year-over-year
- Adjusted EBITDA worsened to negative $3.9 million from negative $3.2 million
- Required two reverse stock splits (1:50 and 1:15) during the quarter
Insights
Applied DNA's Q3 shows declining revenue, continued losses, but strategic repositioning and reduced cash burn following significant restructuring.
Applied DNA's Q3 fiscal 2025 results paint a picture of a company in transition. Revenue declined to
The most promising development is the
On the business development front, Applied DNA secured a follow-on order for LineaDNA valued at over
The strategic pivot to focus exclusively on LineaRx's DNA/mRNA technologies represents a bet on the growing biotherapeutics market, including gene therapies and mRNA applications. This focus on core competencies could streamline operations but also means the company is all-in on the commercial success of its LineaDNA, LineaRNAP, and LineaIVT platforms. The transition from diversified revenue streams to a single business model increases execution risk in the near term.
Notably, the company underwent two reverse stock splits during the period (1:50 in March and 1:15 in June), typically signs of financial distress and attempts to maintain Nasdaq listing requirements. While the company received
STONY BROOK, NY / / August 14, 2025 / (NASDAQ:APDN) ("Applied DNA" or the "Company"), a biotechnology company focused on providing nucleic acid production solutions for the biopharmaceutical and diagnostics industries, today reported financial results for its third quarter of fiscal 2025 ended June 30, 2025. The Company's Form 10-Q for its fiscal third quarter can be viewed on the page of its Investor Relations website. The Company will not host a conference call to discuss these results. Applied DNA investor relations remains available for questions at [email protected] .
Following its previously announced recent restructuring and workforce reductions ("Corporate Actions"), the Company, through its majority-owned LineaRx, Inc. subsidiary, has transitioned to a pure play provider of synthetic DNA and mRNA manufacturing solutions for advanced biotherapeutics, such as gene therapies, personalized medicine, adoptive cell therapies, messenger RNA (mRNA) therapeutics, and DNA vaccines, as well as diagnostic applications that utilize chemically-modified DNA. The Company is commercializing three distinct and complementary technology solutions for DNA production:
尝颈苍别补顿狈础鈩�: A proprietary, cell-free DNA production platform that uses a large-scale PCR process to rapidly and efficiently produce high-fidelity, synthetic DNA as a market-ready alternative to plasmid DNA (pDNA). LineaDNA is applicable to biotherapeutics development and production, serving as the starting material for mRNA therapeutics and vaccines and as a critical component in numerous in vitro diagnostics (IVDs).
尝颈苍别补搁狈础笔鈩�: A next-generation T7 RNA polymerase (RNAP) used to transcribe DNA into mRNA. Designed as a direct replacement for wild-type T7 RNAP currently utilized in conventional IVT mRNA systems that use synthetic or pDNA templates, LineaRNAP incorporates a patented DNA-binding domain that delivers high mRNA yields while reducing double-stranded RNA (dsRNA) contamination, the latter a common byproduct in mRNA production.
尝颈苍别补滨痴罢鈩�: An integrated system that combines the LineaDNA and LineaRNAP technologies and their respective benefits. For mRNA manufacturers, we believe LineaIVT offers reduced dsRNA contamination and expedited mRNA drug substance production, among other advantages.
Management Commentary
"Our operational activities center on repositioning Applied DNA as a single business that is aligned with our proven core competencies, which underpin our commercially available, cell-free DNA and mRNA manufacturing solutions offerings. With operations now right-sized, coupled with active marketing under the LineaRx brand that is now synonymous with synthetically produced DNA, we look forward to delivering value to shareholders," stated Judy Murrah, chairperson, president, and CEO of Applied DNA.
Recent Corporate and Operational Updates
Financial
Monthly net cash burn from operations in the reported quarter declined approximately
19% on a sequential basis and25% compared to the prior year period due to cost-cutting and optimization initiatives implemented in prior quarters. The Company expects a further reduction in the quarter ending September 30, 2025, reflecting the implementation of Corporate Actions.
Customer Acquisition and Repeat Orders
Received a multi-gram follow-on order for LineaDNA valued at over
$600 thousand from a global manufacturer of IVDs for use in a cancer diagnostic application.Added a U.S.-based mRNA contract development manufacturing organization as a customer for LineaDNA IVT templates. This customer is also evaluating LineaRNAP.
Shipped multiple LineaDNA sequences to a U.S.-based developer of a novel vaccine delivery system.
Subsequent to quarter-end, sales quotes were provided to a large public biotech and a multinational biotech tools company for LineaDNA to be used in gene editing applications.
Product and Platform Development
Launched the LineaRx IVT Discovery Kit, which enables potential customers to easily and rapidly evaluate the benefits of LineaDNA and LineaIVT performance against conventional mRNA production methods.
Launched industry marketing for LineaRNAP as a standalone product based on recent Company data confirming that LineaRNAP can be used in conventional mRNA production workflows to enable higher mRNA yields and integrity with reduced dsRNA as compared with conventional wild-type T7 RNAP. The Company also continues to market LineaRNAP as a component of its integrated LineaIVT solution.
Initiated ISO 13485 certification, an internationally recognized quality management standard aligned with GMP, to enhance customer trust, expand market opportunities, and elevate LineaRx's competitive position. The Company expects to be ISO 13485-certified in the first quarter of fiscal 2026.
Participated in multiple mRNA-focused conferences to engage potential customers and showcase its platforms' capabilities as part of LineaRx's ongoing sales and marketing strategy.
Third Quarter Fiscal 2025 Financial Highlights
As part of the Corporate Actions, the Company announced the closure of its MDx Testing Services business segment (Applied DNA Clinical Labs) to focus exclusively on LineaRx. Financial results for the reported and prior periods have been recast to separately report discontinued operations and the results of continuing operations.
In February 2025, the Company announced the wind down of its DNA Tagging and Security Products and Services business segment and continues to terminate business activities in this segment in accordance with customer agreements. Financial results for this segment are included in the results of continuing operations for the reported and prior periods.
Please refer to segment information detailed in the 'Note H - Segment Information' section of the Form 10-Q for the period reported for more information.
On March 13, 2025, the Company filed a Certificate of Amendment of its Certificate of Incorporation with the Secretary of State of the State of Delaware that effected a one-for-fifty (1:50) reverse stock split of its common stock, par value
Summary Financial Results
Total revenues:
$304 thousand compared to$473 thousand in the third quarter of fiscal 2024.Operating loss:
$3.7 million , compared to an operating loss of$3.3 million in the prior period.Adjusted EBITDA: Negative
$3.9 million , compared to negative$3.2 million in the prior period.Monthly net cash burn: Monthly net cash burn from operations in the reported period was
$934 thousand , compared to$1.15 million in the second quarter of fiscal 2025 and$1.25 million in the prior fiscal year period.Cash and cash equivalents as of June 30, 2025:
$4.7 million , which includes$723 thousand of proceeds from the exercise of Series A warrants received during the reported period. Additional proceeds totaling$292 thousand were received subsequent to the reported period from the exercise of Series A warrants.
Information about Non-GAAP Financial Measures
As used herein, "GAAP" refers to accounting principles generally accepted in the United States of America. To supplement our condensed consolidated financial statements prepared and presented in accordance with GAAP, this earnings release includes Adjusted EBITDA and monthly net cash burn from operations, which are non-GAAP financial measures as defined in Rule 101 of Regulation G promulgated by the Securities and Exchange Commission. Generally, a non-GAAP financial measure is a numerical measure of a company's historical or future performance, financial position, or cash flows that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. The presentation of this non-GAAP financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information presented in accordance with GAAP. We use this non-GAAP financial measure for internal financial and operational decision-making purposes and as a means to evaluate period-to-period comparisons of the performance and results of operations of our core businesses. Our management believes that these non-GAAP financial measures provide meaningful supplemental information regarding the performance of our businesses by excluding non-cash expenses that may not be indicative of our recurring operating results. We believe these non-GAAP financial measures are useful to investors as they allow for greater transparency with respect to key metrics used by management in its financial and operational decision making.
"EBITDA" - is defined as earnings (loss) before interest expense, income tax expense and depreciation and amortization expense.
"Adjusted EBITDA" - is defined as EBITDA adjusted to exclude (i) stock-based compensation and (ii) other non-cash expenses and non-cash gains/income.
"Monthly net cash burn" - is defined as total monthly cash outflow, including all operating costs, reduced by cash inflow from revenue.
About Applied DNA Sciences
Applied DNA Sciences is a biotechnology company focused on providing nucleic acid production solutions for the biopharmaceutical and diagnostics industries. Through its majority-owned subsidiary, LineaRx, Inc., the Company is commercializing its 尝颈苍别补顿狈础鈩�, 尝颈苍别补搁狈础笔鈩�, and 尝颈苍别补滨痴罢鈩� platforms to enable the manufacture of next-generation nucleic acid-based therapies.
Visit for more information. Follow us on and . Join our .
Forward-Looking Statements
The statements made by Applied DNA in this press release may be "forward-looking" in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA's future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. These forward-looking statements are based largely on the Company's expectations and projections about future events and future trends affecting our business and are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including statements regarding its goal to position the Company for long-term growth and value creation and the potential to achieve that goal, including the future success of its LineaDNA, LineaRNAP and LineaIVT technologies. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, unknown future ability to remain compliant with all Nasdaq listing standards, unknown future demand for its biotherapeutics products and services, the unknown amount of revenues and profits that will result from its technologies, the fact that there has never been therapeutic clinical trial material and/or a commercial drug product produced utilizing its technologies, whether its restructuring will position the Company for future growth potential, as well as various other factors detailed from time to time in Applied DNA's SEC reports and filings, including its Annual Report on Form 10-K filed on December 17, 2024, Forms 10-Q filed on February 13, 2025, May 15, 2025, and August 14, 2025, and other reports it files with the SEC, which are available at . Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.
Investor Relations contact: Sanjay M. Hurry, 917-733-5573, [email protected]
Web:
X: APDN
- Financial Tables Follow -
APPLIED DNA SCIENCES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
June 30, | September 30, | |||||||
2025 | 2024 | |||||||
ASSETS | (unaudited) | |||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 4,727,677 | $ | 5,852,363 | ||||
Accounts receivable, net of allowance for credit losses of | 199,047 | 328,252 | ||||||
Inventories | 338,723 | 432,725 | ||||||
Prepaid expenses and other current assets | 338,447 | 756,185 | ||||||
Current assets of discontinued operations | 25,008 | 678,146 | ||||||
Total current assets | 5,628,902 | 8,047,671 | ||||||
Property and equipment, net | 511,203 | 458,895 | ||||||
Noncurrent assets of discontinued operations | 11,264 | 94,337 | ||||||
Other assets: | ||||||||
Restricted cash | 750,000 | 750,000 | ||||||
Intangible assets | 2,698,975 | 2,698,975 | ||||||
Operating right of use asset | 334,402 | 739,162 | ||||||
Total assets | $ | 9,934,746 | $ | 12,789,040 | ||||
LIABILITIES AND EQUITY | ||||||||
Current liabilities: | ||||||||
Accounts payable and accrued liabilities | $ | 1,564,707 | $ | 1,737,366 | ||||
Operating lease liability, current | 334,403 | 545,912 | ||||||
Deferred revenue | 12,285 | 58,785 | ||||||
Current liabilities of discontinued operations | 124,565 | 56,061 | ||||||
Total current liabilities | 2,035,960 | 2,398,124 | ||||||
Long term accrued liabilities | 31,467 | 31,467 | ||||||
Deferred revenue, long term | 194,000 | 194,000 | ||||||
Operating lease liability, long term | - | 193,249 | ||||||
Deferred tax liability, net | 684,115 | 684,115 | ||||||
Warrants classified as a liability | 1,160 | 320,000 | ||||||
Total liabilities | 2,946,702 | 3,820,955 | ||||||
Commitments and contingencies (Note G) | ||||||||
Applied DNA Sciences, Inc. stockholders' equity: | ||||||||
Preferred stock, par value | - | - | ||||||
Series A Preferred stock, par value | - | - | ||||||
Series B Preferred stock, par value | - | - | ||||||
Common stock, par value | 902 | 14 | ||||||
Additional paid in capital | 381,150,267 | 318,815,358 | ||||||
Accumulated deficit | (373,888,601 | ) | (309,672,755 | ) | ||||
Applied DNA Sciences, Inc. stockholders' equity | 7,262,568 | 9,142,617 | ||||||
Noncontrolling interest | (274,524 | ) | (174,532 | ) | ||||
Total equity | 6,988,044 | 8,968,085 | ||||||
Total liabilities and equity | $ | 9,934,746 | $ | 12,789,040 | ||||
APPLIED DNA SCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
Three months Ended June 30, | Nine months Ended June 30, | |||||||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||||||
Revenues | ||||||||||||||||
Product revenues | $ | 195,262 | $ | 246,644 | $ | 1,239,747 | $ | 947,086 | ||||||||
Service revenues | 109,131 | 226,145 | 697,759 | 678,777 | ||||||||||||
Total revenues | 304,393 | 472,789 | 1,937,506 | 1,625,863 | ||||||||||||
Cost of product revenues | 299,263 | 230,188 | 930,619 | 853,034 | ||||||||||||
Gross profit | 5,130 | 242,601 | 1,006,887 | 772,829 | ||||||||||||
Operating expenses: | ||||||||||||||||
Selling, general and administrative | 2,930,627 | 2,635,863 | 8,423,602 | 8,440,919 | ||||||||||||
Research and development | 768,563 | 913,031 | 2,632,931 | 2,762,040 | ||||||||||||
Total operating expenses | 3,699,190 | 3,548,894 | 11,056,533 | 11,202,959 | ||||||||||||
LOSS FROM OPERATIONS | (3,694,060 | ) | (3,306,293 | ) | (10,049,646 | ) | (10,430,130 | ) | ||||||||
Interest income | 40,267 | 29,688 | 168,762 | 33,989 | ||||||||||||
Transaction costs allocated to warrant liabilities | - | - | - | (633,198 | ) | |||||||||||
Unrealized gain on change in fair value of warrants classified as a liability | 6,410 | 5,160,000 | 318,840 | 9,564,000 | ||||||||||||
Unrealized loss on change in fair value of warrants classified as a liability - warrant modification | - | - | - | (394,000 | ) | |||||||||||
Loss on issuance of warrants | - | - | - | (1,633,767 | ) | |||||||||||
Other expense, net | (531 | ) | (103 | ) | (23,778 | ) | (9,060 | ) | ||||||||
(Loss) income before provision for income taxes | (3,647,914 | ) | 1,883,292 | (9,585,822 | ) | (3,502,166 | ) | |||||||||
Provision for income taxes | - | - | - | - | ||||||||||||
Net (loss) income from continuing operations | $ | (3,647,914 | ) | $ | 1,883,292 | $ | (9,585,822 | ) | $ | (3,502,166 | ) | |||||
Net loss from discontinued operations, net of tax | (336,195 | ) | (33,791 | ) | (403,120 | ) | (272,397 | ) | ||||||||
NET (LOSS) INCOME | $ | (3,984,109 | ) | $ | 1,849,501 | $ | (9,988,942 | ) | $ | (3,774,563 | ) | |||||
Less: Net loss attributable to noncontrolling interest | 38,746 | 30,295 | 99,992 | 78,785 | ||||||||||||
NET (LOSS) INCOME attributable to Applied DNA Sciences, Inc. | $ | (3,945,363 | ) | $ | 1,879,796 | $ | (9,888,950 | ) | $ | (3,695,778 | ) | |||||
Deemed dividend related to warrant modifications | (15,500,244 | ) | - | (54,326,896 | ) | (233,087 | ) | |||||||||
NET (LOSS) INCOME attributable to common stockholders | $ | (19,445,607 | ) | $ | 1,879,796 | $ | (64,215,846 | ) | $ | (3,928,865 | ) | |||||
Net (loss) income per share attributable to common stockholders-basic and diluted from continuing operations | $ | (33.41 | ) | $ | 1,191.52 | $ | (255.14 | ) | $ | (4,862.32 | ) | |||||
Net loss per share attributable to common stockholders-basic and diluted from discontinued operations | (0.59 | ) | (21.04 | ) | (1.61 | ) | (362.23 | ) | ||||||||
Net (loss) income per share attributable to common stockholders-basic and diluted | $ | (34.00 | ) | $ | 1,170.48 | $ | (256.75 | ) | $ | (5,224.55 | ) | |||||
Weighted average shares outstanding- basic and diluted | 572,018 | 1,606 | 250,107 | 752 | ||||||||||||
APPLIED DNA SCIENCES, INC.
CALCULATION AND RECONCILIATION OF ADJUSTED EBITDA
(unaudited)
Three-Month Period Ended June 30, | ||||||||
2025 | 2024 | |||||||
Net loss | $ | (3,984,109 | ) | $ | 1,849,501 | |||
Interest income | (40,267 | ) | (29,688 | ) | ||||
Depreciation and amortization | 78,346 | 134,163 | ||||||
Stock-based compensation expense | 24,889 | 30,336 | ||||||
Unrealized (loss) on change in fair value of warrants classified as a liability | (6,410 | ) | (5,160,000 | ) | ||||
Total non-cash items | 56,558 | (5,025,189 | ) | |||||
Consolidated Adjusted EBITDA (loss) | $ | (3,927,551 | ) | $ | (3,175,688 | ) | ||
SOURCE: Applied DNA Sciences, Inc.
View the original on ACCESS Newswire
FAQ
What were Applied DNA's (APDN) key financial results for Q3 2025?
What major strategic changes did Applied DNA implement in Q3 2025?
What are Applied DNA's three main technology solutions?
What significant orders did Applied DNA receive in Q3 2025?
How many reverse stock splits did APDN implement in Q3 2025?
